Fabio Zani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabio Zani has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Becattini
The Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
2 shared publications Claudia Sardi
2 shared publications- Giovanni Solinas
The Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
2 shared publications - Ludovic Breasson
The Wallenberg Laboratory, Department of Molecular and Clinical Medicine at Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
2 shared publications - Alessandro Provenzani
University of Trento
1 shared publication - Angela Molinaro
University of Gothenburg
1 shared publication
Latest Publications
- Open Access
- 13 February 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol
Background: Kidney transplantation is the most effective treatment for patients with end-stage kidney disease. Modern immunosuppressive treatment has prolonged graft survival and reduced transplant rejection. However, these immunosuppressive regimens are associated with multiple side effects, including increased infections and cancer risk, nephrotoxicity, and metabolic complications. Attaining transplant tolerance with minimal reliance on immunosuppressive drugs is considered the ultimate goal in transplantation. Regulatory T cells (Tregs) adoptive immunotherapy has been proposed as a strategy to achieve transplant tolerance. However, this approach is labor-intensive and expensive, limiting its large-scale applicability. There is, therefore, a need to develop methods that promote Treg-mediated tolerance in vivo . Treg function and numbers are influenced by dietary components, and dietary interventions could provide a new therapeutic opportunity. Recently, our group demonstrated that sucralose supplementation, a commonly used sugar substitute (sweetener), reduces proinflammatory T-cell function and unpublished data indicating enhanced Treg frequencies. Building on this discovery, we propose to investigate the impact of sucralose on modulating T-cell populations and function in humans. Objective: To determine whether sucralose supplementation increases circulating Treg frequencies and alters T-cell function and populations in healthy adults. Design: This is a randomized, double-blind, placebo-controlled, crossover pilot trial. Setting: The study will be monocentric, at the Maisonneuve-Rosemont Hospital. Patients: Twelve healthy adult volunteers (>18 years of age), of both sexes, with no prior history of autoimmune disease or current treatments of immunomodulatory drugs. In addition, pregnant women will also be excluded from this study. Measurements: The primary outcome will be an alteration in circulating Treg frequency after sucralose supplementation. The secondary outcomes include modulation in the frequency of CD45 + cells, the frequency of CD4 + T-cell subsets, the differentiation of both CD4 + and CD8 + T cells, and T-cell function after antigen-specific and alloreactive challenges. Feasibility will also be evaluated, including adherence to visits, blood draw, ease of recruitment, percentage of study completion, and adherence to supplements. Exploratory outcomes in response to sucralose supplementation include changes in circulating metabolites and gut microbiome composition. Methods: Participants will be randomly assigned to receive either a placebo or sucralose (5–7 mg/kg/day) for four weeks, separated by a two-week washout period. This will be followed by a crossover phase, where patients receiving sucralose will receive the placebo and vice versa for an additional four weeks. Capsules will be prepared and blinded by a licensed pharmacy. Blood will be collected at baseline, after four weeks of treatment or placebo, after washout and after four weeks of crossover for Peripheral Blood Mononuclear Cell (PBMC) isolation, flow cytometry, functional assays, and metabolomics. Stool samples will be collected for microbiome sequencing. Limitations: This will be a small, single-center, short-duration trial in healthy volunteers. Findings might not apply to transplant recipients. Conclusion: The SWEET trial will provide first-in-human data on sucralose as a potential, inexpensive oral immunomodulator to promote Tregs. Trial Registration: NCT06997133 (2025-06-05)
- 13 February 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Open AccessSucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol
Background: Kidney transplantation is the most effective treatment for patients with end-stage kidney disease. Modern immunosuppressive treatment has prolonged graft survival and reduced transplant rejection. However, these immunosuppressive regimens are associated with multiple side effects, including increased infections and cancer risk, nephrotoxicity, and metabolic complications. Attaining transplant tolerance with minimal reliance on immunosuppressive drugs is considered the ultimate goal in transplantation. Regulatory T cells (Tregs) adoptive immunotherapy has been proposed as a strategy to achieve transplant tolerance. However, this approach is labor-intensive and expensive, limiting its large-scale applicability. There is, therefore, a need to develop methods that promote Treg-mediated tolerance in vivo . Treg function and numbers are influenced by dietary components, and dietary interventions could provide a new therapeutic opportunity. Recently, our group demonstrated that sucralose supplementation, a commonly used sugar substitute (sweetener), reduces proinflammatory T-cell function and unpublished data indicating enhanced Treg frequencies. Building on this discovery, we propose to investigate the impact of sucralose on modulating T-cell populations and function in humans. Objective: To determine whether sucralose supplementation increases circulating Treg frequencies and alters T-cell function and populations in healthy adults. Design: This is a randomized, double-blind, placebo-controlled, crossover pilot trial. Setting: The study will be monocentric, at the Maisonneuve-Rosemont Hospital. Patients: Twelve healthy adult volunteers (>18 years of age), of both sexes, with no prior history of autoimmune disease or current treatments of immunomodulatory drugs. In addition, pregnant women will also be excluded from this study. Measurements: The primary outcome will be an alteration in circulating Treg frequency after sucralose supplementation. The secondary outcomes include modulation in the frequency of CD45 + cells, the frequency of CD4 + T-cell subsets, the differentiation of both CD4 + and CD8 + T cells, and T-cell function after antigen-specific and alloreactive challenges. Feasibility will also be evaluated, including adherence to visits, blood draw, ease of recruitment, percentage of study completion, and adherence to supplements. Exploratory outcomes in response to sucralose supplementation include changes in circulating metabolites and gut microbiome composition. Methods: Participants will be randomly assigned to receive either a placebo or sucralose (5–7 mg/kg/day) for four weeks, separated by a two-week washout period. This will be followed by a crossover phase, where patients receiving sucralose will receive the placebo and vice versa for an additional four weeks. Capsules will be prepared and blinded by a licensed pharmacy. Blood will be collected at baseline, after four weeks of treatment or placebo, after washout and after four weeks of crossover for Peripheral Blood Mononuclear Cell (PBMC) isolation, flow cytometry, functional assays, and metabolomics. Stool samples will be collected for microbiome sequencing. Limitations: This will be a small, single-center, short-duration trial in healthy volunteers. Findings might not apply to transplant recipients. Conclusion: The SWEET trial will provide first-in-human data on sucralose as a potential, inexpensive oral immunomodulator to promote Tregs. Trial Registration: NCT06997133 (2025-06-05)
- 2 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (3) , 569-570
Drink Responsibly: Cancer Cells Also Like Sugary Drinks
Sugar-sweetened beverages (SSB), which contain both glucose and fructose, have been linked to an increased incidence of colorectal cancer. Their effects on colorectal cancer progression, however, are unclear. In their recent work, Feng and colleagues investigated how exposure to SSBs affects colorectal cancer metastasis. They discovered that several colorectal cancer cell lines showed enhanced migration when exposed to glucose and fructose together, compared with cells exposed to glucose or fructose alone. Similarly, in mouse models of colorectal cancer liver metastasis, mice fed both glucose and fructose developed more liver metastases, suggesting that SSBs promote colorectal cancer spread. Leveraging metabolomic analyses, they discovered that in the presence of both glucose and fructose, the enzyme sorbitol dehydrogenase (SORD) converts fructose to sorbitol, regenerating NAD+ from NADH. Deleting SORD reduced the NAD+/NADH ratio and colorectal cancer cell migration and metastasis. Restoring the NAD+/NADH ratio rescued migration, suggesting that SORD-driven NAD+ regeneration promotes metastatic behavior. Furthermore, they demonstrated that increased NAD+/NADH levels have a profound effect on cell metabolism, supporting glycolysis, the TCA cycle, and the mevalonate pathway. Interestingly, pharmacologic inhibition of the mevalonate pathway with statins reduced cell migration and liver metastasis in mice consuming SSBs. Together, these findings demonstrate that SSBs enhance colorectal cancer metastasis through SORD-dependent metabolic reprogramming. By regenerating NAD+ and glycolysis and supporting the mevalonate pathway, SORD links SSB consumption to increased tumor cell migration and metastatic potential.
- 2 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (3) , 569-570
Drink Responsibly: Cancer Cells Also Like Sugary Drinks
Sugar-sweetened beverages (SSB), which contain both glucose and fructose, have been linked to an increased incidence of colorectal cancer. Their effects on colorectal cancer progression, however, are unclear. In their recent work, Feng and colleagues investigated how exposure to SSBs affects colorectal cancer metastasis. They discovered that several colorectal cancer cell lines showed enhanced migration when exposed to glucose and fructose together, compared with cells exposed to glucose or fructose alone. Similarly, in mouse models of colorectal cancer liver metastasis, mice fed both glucose and fructose developed more liver metastases, suggesting that SSBs promote colorectal cancer spread. Leveraging metabolomic analyses, they discovered that in the presence of both glucose and fructose, the enzyme sorbitol dehydrogenase (SORD) converts fructose to sorbitol, regenerating NAD+ from NADH. Deleting SORD reduced the NAD+/NADH ratio and colorectal cancer cell migration and metastasis. Restoring the NAD+/NADH ratio rescued migration, suggesting that SORD-driven NAD+ regeneration promotes metastatic behavior. Furthermore, they demonstrated that increased NAD+/NADH levels have a profound effect on cell metabolism, supporting glycolysis, the TCA cycle, and the mevalonate pathway. Interestingly, pharmacologic inhibition of the mevalonate pathway with statins reduced cell migration and liver metastasis in mice consuming SSBs. Together, these findings demonstrate that SSBs enhance colorectal cancer metastasis through SORD-dependent metabolic reprogramming. By regenerating NAD+ and glycolysis and supporting the mevalonate pathway, SORD links SSB consumption to increased tumor cell migration and metastatic potential.
- 18 July 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (488)
PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity
The kinase PI3Kγ aggravates obesity by activating macrophages and triggering inflammation in adipose tissue.
- 18 July 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (488)
PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity
The kinase PI3Kγ aggravates obesity by activating macrophages and triggering inflammation in adipose tissue.
- Open Access
- 26 May 2016
- Published by Wiley in The FASEB Journal
- Vol. 30 (9) , 3124-3132
JNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage
Obesity and insulin resistance are associated with oxidative stress, which may be implicated in the progression of obesity‐related diseases. The kinase JNK1 has emerged as a promising drug target for the treatment of obesity and type 2 diabetes. JNK1 is also a key mediator of the oxidative stress response, which can promote cell death or survival, depending on the magnitude and context of its activation. In this article, we describe a study in which the long‐term effects of JNK1 inactivation on glucose homeostasis and oxidative stress in obese mice were investigated for the first time. Mice lacking JNK1 (JNK1 –/– ) were fed an obesogenic high‐fat diet (HFD) for a long period. JNK1 –/– mice fed an HFD for the long term had reduced expression of antioxidant genes in their skin, more skin oxidative damage, and increased epidermal thickness and inflammation compared with the effects in control wild‐type mice. However, we also observed that the protection from obesity, adipose tissue inflammation, steatosis, and insulin resistance, conferred by JNK1 ablation, was sustained over a long period and was paralleled by decreased oxidative damage in fat and liver. We conclude that compounds targeting JNK1 activity in brain and adipose tissue, which do not accumulate in the skin, may be safer and most effective.—Becattini, B., Zani, F., Breasson, L., Sardi, C., D'Agostino, V. G., Choo, M.‐K., Provenzani, A., Park, J. M., Solinas, G. JNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage. FASEBJ. 30, 3124–3132 (2016). www.fasebj.org
- 26 May 2016
- Published by Wiley in The FASEB Journal
- Vol. 30 (9) , 3124-3132
Open AccessJNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage
Obesity and insulin resistance are associated with oxidative stress, which may be implicated in the progression of obesity‐related diseases. The kinase JNK1 has emerged as a promising drug target for the treatment of obesity and type 2 diabetes. JNK1 is also a key mediator of the oxidative stress response, which can promote cell death or survival, depending on the magnitude and context of its activation. In this article, we describe a study in which the long‐term effects of JNK1 inactivation on glucose homeostasis and oxidative stress in obese mice were investigated for the first time. Mice lacking JNK1 (JNK1 –/– ) were fed an obesogenic high‐fat diet (HFD) for a long period. JNK1 –/– mice fed an HFD for the long term had reduced expression of antioxidant genes in their skin, more skin oxidative damage, and increased epidermal thickness and inflammation compared with the effects in control wild‐type mice. However, we also observed that the protection from obesity, adipose tissue inflammation, steatosis, and insulin resistance, conferred by JNK1 ablation, was sustained over a long period and was paralleled by decreased oxidative damage in fat and liver. We conclude that compounds targeting JNK1 activity in brain and adipose tissue, which do not accumulate in the skin, may be safer and most effective.—Becattini, B., Zani, F., Breasson, L., Sardi, C., D'Agostino, V. G., Choo, M.‐K., Provenzani, A., Park, J. M., Solinas, G. JNK1 ablation in mice confers long‐term metabolic protection from diet‐induced obesity at the cost of moderate skin oxidative damage. FASEBJ. 30, 3124–3132 (2016). www.fasebj.org